ABSTRACT
Background Understanding humoral responses and seroprevalence in SARS-CoV-2 infection is essential for guiding vaccination strategies in both infected and uninfected individuals.
Methods We determine the kinetics of IgM against the nucleocapsid (N) and IgG against the spike (S) and N proteins of SARS-CoV-2 in a cohort of 860 health professionals (healthy and infected) in northern Barcelona. We model the kinetics of IgG and IgM at nine time points over 13.5 months from infection, using non-linear mixed models by sex and clinical disease severity.
Results Of the 781 participants who were followed up, 478 (61.2%) became infected with SARS-CoV-2. Significant differences were found for the three antibodies by disease severity and sex. At day 270 after diagnosis, median IgM(N) levels were already below the positivity threshold in patients with asymptomatic and mild-moderate disease, while IgG(N, S) levels remained positive to days 360 and 270, respectively. Kinetic modelling showed a general rise in both IgM(N) and IgG(N) levels up to day 30, followed by a decay whose rate depended on disease severity. IgG(S) levels increased at day 15 and remained relatively constant over time.
Conclusions We describe kinetic models of IgM(N) and IgG(N, S) SARS-CoV-2 antibodies at 13.5 months from infection and disease spectrum. Our analyses delineate differences in the kinetics of IgM and IgG over a year and differences in the levels of IgM and IgG as early as 15 days from symptoms onset in severe cases. These results can inform public health policies around vaccination criteria.
Funded by the regional Ministry of Health of the Generalitat de Catalunya (Call COVID19-PoC SLT16_04; NCT04885478)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04885478
Funding Statement
This project has been funding by Funded by the regional Ministry of Health of the Generalitat de Catalunya (Call COVID19-PoC SLT16_04) and partially funded by the Carlos III Health Institute (Ministry of Economy and Competitiveness, Spain) through the Network for Prevention and Health Promotion in Primary Care (redIAPP, RD16/0007/0001), and by European Union European Regional Development Fund (ERDF) funds (European Regional Development Fund), and Catalan Government (Grant Number AGAUR 2017 SGR 445), and PI19 Contratos predoctorales de formacion en investigacion en salud (AES 2019). PFIS Grant number FI20/00040.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committees: The Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol). https://www.idiapjgol.org/index.php/en/ Reference ref 20/067 The Germans Trias i Pujol Research Institute(IGTP) http://www.germanstrias.org/ Reference COV20/00660 (PI-20-205)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** Last shared authorship
Data Availability
The study data will not be openly available. If researchers or institutions are interested in the data, the authors will be able to release the data after asking the study participants for their consent and signing the relevant legal agreements allowing the data to be released to third parties.
